Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 6/20 | 0.38 |
| ▸ | MAN2B1 | O00754 | 2/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.37 |
| ▸ | AURKA | O14965 | 2/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | PAK4 | O96013 | 1/20 | 0.36 |
| ▸ | PRKCG | P05129 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3881981 | 1.00 | MAPKAPK2 (0.44) | MAPKAPK2CYP1A2POLBEGFRMAN2B1 | |
| SCHEMBL14272149 | 0.82 | EGFR (0.41) | CYP1A2POLBEGFRRPS6KB1AURKA | |
| SCHEMBL4959364 | 0.81 | CYP1A2 (0.43) | CYP1A2POLBMAN2B1RPS6KB1AURKA | |
| SCHEMBL4959362 | 0.81 | CYP1A2 (0.43) | CYP1A2POLBMAN2B1RPS6KB1AURKA | |
| SCHEMBL14452553 | 0.78 | KMT2A (0.47) | CYP1A2POLBROCK2ROCK1RPS6KA5 | |
| SCHEMBL4958491 | 0.70 | CYP1A2 (0.47) | CYP1A2POLB | |
| SCHEMBL10526965 | 0.68 | RIPK1 (0.49) | MAPKAPK2MAN2B1RPS6KB1RIPK1ROCK2 | |
| SCHEMBL20095129 | 0.67 | MAPKAPK2 (0.54) | MAPKAPK2CYP1A2EGFRRPS6KB1RIPK1 | |
| SCHEMBL430689 | 0.67 | MAPKAPK2 (0.54) | MAPKAPK2CYP1A2EGFRRPS6KB1RIPK1 | |
| SCHEMBL27783713 | 0.67 | MAPKAPK2 (0.54) | MAPKAPK2CYP1A2EGFRRPS6KB1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1805175-B1 | NOVEL AZAINDOLE THIAZOLINONES AS ANTI-CANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2008-03-05 | — | — | EP | disclosed |
| CN-101046471-A | Tumor models employing green fluorescent protein | HOFFMANN LA ROCHE (CH) | 2007-10-03 | — | — | CN | disclosed |
| CN-101023080-A | Thiazolinone 4-monosubstituted quinolines | HOFFMANN LA ROCHE (CH) | 2007-08-22 | — | — | CN | disclosed |
| US-7253285-B2 | Thiazolinone 4-monosubstituted quinolines | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7247727-B2 | Azaindole thiazolinones | HOFFMANN-LA ROCHE INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1805175-A1 | NOVEL AZAINDOLE THIAZOLINONES AS ANTI-CANCER AGENTS | F. Hoffmann-Roche AG (CH) | 2007-07-11 | — | — | EP | disclosed |
| EP-1797085-A1 | THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES | F. Hoffmann-Roche AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| CN-1976927-A | Quinoline thiazolinone compound | HOFFMANN LA ROCHE (CH) | 2007-06-06 | — | — | CN | disclosed |
| US-20060084674-A1 | Azaindole thiazolinones | CHEN SHAOQING | 2006-04-20 | — | — | US | disclosed |
| WO-2006040049-A1 | NOVEL AZAINDOLE THIAZOLINONES AS ANTI-CANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | WO | disclosed |
| US-20060063805-A1 | Thiazolinone 4-monosubstituted quinolines | CHEN LI | 2006-03-23 | — | — | US | disclosed |
| WO-2006029861-A1 | THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063805-A1 | Thiazolinone 4-monosubstituted quinolines | CDK1, CDK14, CDK17 | MAPKAPK2 410/4885CYP1A2 3343/4885POLB 725/4885 |
| US-20060084674-A1 | Azaindole thiazolinones | CDK1, CDK2, CDK12 | MAPKAPK2 249/4885CYP1A2 3707/4885POLB 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.